Skip To Main Content
Ruweida Mohamed Bundid on Muck Rack

Ruweida Mohamed Bundid

As seen in: medRxiv, Preprints.org
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruweida Mohamed

Contact Ruweida Mohamed, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mortality Trends and Disparities Associated with Hepatic Vascular Diseases in the United States, 1999–2024: A CDC WONDER Multiple-Cause-of-Death Analysis

|
By Khaled Hamed, Ruweida Mohamed Bundid, Maha Ali Sayah
| Preprints.org
This version is not peer-reviewed. Khaled Hamed  * ,Ruweida Bundid ,Maha Sayah Khaled Hamed  * ,Ruweida Bundid ,Maha Sayah Submitted: 27 September 2026 You are already at the latest version Background: Hepatic vascular diseases (HVDs)—encompassing portal inflow, sinusoidal microcirculatory, hepatic venous outflow, and hepatic arterial disorders—cause severe portal hypertension, liver failure, and death.
Open in Who Shared Issue with article?

National trends, demographic disparities, and phenotypic shifts in encephalopathy-associated mortality in the United States: A CDC WONDER analysis, 1999-2024

|
By Maha Ali Sayah, Ruweida Mohamed Bundid, Ondokuz Mayiz
| medRxiv
The authors have declared no competing interest. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used only openly available, de-identified human mortality data from the Centers for Disease Control and Prevention (CDC) WONDER database, available at https://wonder.cdc.gov/.
Open in Who Shared View Duplicates (37) Issue with article?

Internal Dose Benchmarking of Acrylamide Exposure and Peripheral Neuropathy Risk: A National Population-Based Validation Study

|
By Mohamed Gamal, Ruweida Mohamed Bundid, Maha Ali Sayah
| medRxiv
The authors have declared no competing interest. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The data used in this study are publicly available from the National Health and Nutrition Examination Survey (NHANES) database (https://www.cdc.gov/nchs/nhanes/about/index.html).
Open in Who Shared View Duplicates (70) Issue with article?
See all 3 articles